Effect of half-dose and standard-dose conjugated equine estrogens combined with natural progesterone or dydrogesterone on components of metabolic syndrome in healthy postmenopausal women: A randomized controlled trial

Chinese Medical Journal

Volumn 129, Issue 23, 2016, Pages 2773-2779

  Xue, Wei ^a   Deng, Yan ^a   Wang, Yan Fang ^a   Sun, Ai Jun ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Chinese postmenopausal women; Conjugated equine estrogen; Dydrogesterone; Menopausal hormone therapy; Micronized progesterone

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; CONJUGATED ESTROGEN; DYDROGESTERONE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROGESTERONE; TRIACYLGLYCEROL; INSULIN; LIPOPROTEIN A;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BODY COMPOSITION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE SEQUENCE; FEMALE; HUMAN; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; INTENTION TO TREAT ANALYSIS; METABOLIC SYNDROME X; MIDDLE AGED; NORMAL HUMAN; OPEN STUDY; OUTCOME ASSESSMENT; POSTMENOPAUSE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; BLOOD; BLOOD PRESSURE; DRUG EFFECTS;

APOLIPOPROTEINS B; BLOOD PRESSURE; BODY COMPOSITION; DYDROGESTERONE; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; INSULIN; LIPOPROTEIN(A); METABOLIC SYNDROME X; MIDDLE AGED; POSTMENOPAUSE; PROGESTERONE; TRIGLYCERIDES;

EID: 84998678081     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.4103/0366-6999.194646     Document Type: Article

References (24)

1. Spencer CP, Godsland IF, Stevenson JC. Is there a menopausal metabolic syndrome? Gynecol Endocrinol 1997;11:341-55. doi:10.3109/09513599709152559.
2. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607. doi:10.2337/diab.37.12.1595.
3. Lovre D, Lindsey SH, Mauvais-Jarvis F. Effect of menopausal hormone therapy on components of the metabolic syndrome. Ther Adv Cardiovasc Dis 2016. pii: 1753944716649358. [Epub ahead of print]. doi:10.1177/1753944716649358.
4. Manson JE. Current recommendations: What is the clinician to do? Fertil Steril 2014;101:916-21. doi:10.1016/j.fertnstert.2014.02.043.
5. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: Analysis of studies published from 1974-2000. Fertil Steril 2001;75:898-915. doi:10.1016/S0015-0282(01)01699-5.
6. Lobo RA, Pinkerton JV, Gass ML, Dorin MH, Ronkin S, Pickar JH, et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009;92:1025-38. doi:10.1016/j.fertnstert.2009.03.113.
7. Margolis KL, Bonds DE, Rodabough RJ, Tinker L, Phillips LS, Allen C, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: Results from the Women’s Health Initiative Hormone Trial. Diabetologia 2004;47:1175-87. doi:10.1007/s00125-004-1448-x.
8. Kanaya AM, Herrington D, Vittinghoff E, Lin F, Grady D, Bittner V, et al. Glycemic effects of postmenopausal hormone therapy: The Heart and Estrogen/Progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003;138:1-9. doi:10.7326/0003-4819-138-1-200301070-00005.
9. Jensen LB, Vestergaard P, Hermann AP, Gram J, Eiken P, Abrahamsen B, et al. Hormone replacement therapy dissociates fat mass and bone mass, and tends to reduce weight gain in early postmenopausal women: A randomized controlled 5-year clinical trial of the Danish Osteoporosis Prevention Study. J Bone Miner Res 2003;18:333-42. doi:10.1359/jbmr.2003.18.2.333.
10. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995;273:199-208. doi:10.1001/jama.1995.03520270033028.
11. Geloneze B, Repetto EM, Geloneze SR, Tambascia MA, Ermetice MN. The threshold value for insulin resistance (HOMA-IR) in an admixtured population IR in the Brazilian metabolic syndrome study. Diabetes Res Clin Pract 2006;72:219-20. doi:10.1016/j.diabres.2005.10.017.
12. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13. doi:10.1001/jama.280.7.605.
13. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women’s health initiative randomized controlled trial. JAMA 2002;288:321-33. doi:10.1001/jama.288.3.321.
14. Lobo RA, Pickar JH, Wild RA, Walsh B, Hirvonen E. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. The Menopause Study Group. Obstet Gynecol 1994;84:987-95.
15. Espeland MA, Hogan PE, Fineberg SE, Howard G, Schrott H, Waclawiw MA, et al. Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Diabetes Care 1998;21:1589-95. doi:10.2337/diacare.21.10.1589.
16. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939-53. doi:10.7326/0003-4819-135-11-200112040-00005.
17. Sargeant LA, Wareham NJ, Khaw KT. Hormone replacement therapy and glucose tolerance in EPIC-Norfolk: A population-based study. Diabetes Metab Res Rev 2000;16:20-5. doi:10.1002/(SICI)1520-7560(200001/02)16:1<20::AID-DMRR76>3.0.CO;2-A.
18. Zhang Y, Howard BV, Cowan LD, Yeh J, Schaefer CF, Wild RA, et al. The effect of estrogen use on levels of glucose and insulin and the risk of type 2 diabetes in american Indian postmenopausal women: The strong heart study. Diabetes Care 2002;25:500-4. doi:10.2337/diacare.25.3.500.
19. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med 1993;328:1069-75. doi:10.1056/NEJM199304153281501.
20. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women’s Health Initiative randomized controlled trial. JAMA 2004;291:1701-12. doi:10.1001/jama.291.14.1701.
21. Kong D, Zhan Y, Liu Z, Ding T, Li M, Yu H, et al. SIRT1-mediated ERß suppression in the endothelium contributes to vascular aging. Aging Cell 2016. [Epub ahead of print]. doi:10.1111/acel.12515.
22. Liu Z, Gou Y, Zhang H, Zuo H, Zhang H, Liu Z, et al. Estradiol improves cardiovascular function through up-regulation of SOD2 on vascular wall. Redox Biol 2014;3:88-99. doi:10.1016/j.redox.2014.11.001.
23. Matrai M, Hetthéssy JR, Nadasy GL, Szekacs B, Mericli M, Acs N, et al. Estrogen therapy may counterbalance eutrophic remodeling of coronary arteries and increase bradykinin relaxation in a rat model of menopausal hypertension. Menopause 2016;23:778-83. doi:10.1097/GME.0000000000000654.
24. Tarhouni K, Guihot AL, Vessieres E, Procaccio V, Grimaud L, Abraham P, et al. Estrogens are needed for the improvement in endothelium-mediated dilation induced by a chronic increase in blood flow in rat mesenteric arteries. Vascul Pharmacol 2016;80:35-42. doi:10.1016/j.vph.2015.10.004.